Jun 09, 2023 / 02:30PM GMT
Andrew Tsai - Jefferies LLC - Analyst
It's my pleasure to have the Savara team with me today. To the left of me, Matt Pauls, Chairman and CEO, and to the left of him, Ray Pratt, CMO. Welcome both of you.
Matt Pauls - Savara Inc. - Chair of the Board of Directors & CEO
Thank you very much.
Andrew Tsai - Jefferies LLC - Analyst
So Matt, Ray, for those in the audience who may be less familiar with the Savara story, maybe give us an overview about your program. What your lead drug is, and what the status is, and the milestones we can look forward to over the next 6 to 12 months?
Matt Pauls - Savara Inc. - Chair of the Board of Directors & CEO
Sure. Thank you, Andrew. I'm Matt Pauls, Chair and CEO of Savara. I'm joined by my colleague, Dr. Ray Pratt, our Chief Medical Officer. Thanks for the invite.
Savara is a rare respiratory-focused company. Single asset, late-stage Phase 3 program. And we have a novel inhaled biologic called molgramostim nebulizer solution.
Savara Inc at Jefferies Healthcare Conference Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers